Carcinogenicity testing in the CD-1 mouse of a prospective insect repellent (KBR 3023) using the dermal route of...

The carcinogenic potential of 1-(1-methyl-propoxycarbonyl)-2-(2-hydroxyethyl)-piperidine (KBR 3023), a prospective new insect repellent intended for human use, was studied in mice using the dermal route of application. Relying upon the toxicology profile that emerged in the subchronic rat bioassay that was conducted using dermally applied dosages of 0, 80, 200, 500, and 1000 mg KBR 3023/kg body weight per day, it was determined, in concert with the EPA, that dermally applied dosages of 0, 50, 100, or 200 mg KBR 3023/kg body weight per day would be used in the conduct of all definitive forms of subchronic, chronic, and lifetime descriptive testing performed with the chemical. Using this testing approach, the specific results of this 18-month study are as follows. All in-life parameters, which included body weight, food consumption, clinical observations, survival, and hematology were unaffected by exposure to KBR 3023. Similarly, postmortem analyses, which included organ weights and gross pathology, and histopathology were also unchanged following exposure to KBR 3023. No evidence of a compound-induced neoplasia was suggested in this bioassay.